Together, these findings suggest that ERas may potentiate the activities of pancreatic cancer cells through the Erk and Akt pathway, suggesting that these pathways may represent a suitable target for the therapeutic treatment of pancreatic cancer. This evidence concerns the gene ERAS and pancreatic neoplasm.